CDIO

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) is a biotechnology company founded in 2017 and headquartered in Chicago, Illinois. The company went public in January 2022 and specializes in developing and commercializing advanced diagnostic tests for cardiovascular disease using epigenetic technology. As a relatively young public company in the precision medicine space, Cardio Diagnostics focuses on creating innovative testing solutions that can help predict and assess cardiovascular risk before symptoms appear.